We use cookies to deliver our online services. Details of the cookies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you agree to our use of cookies. To close this message click close.

OIG Report and Special Advisory Bulletin Identify Vulnerabilities in Copay Coupon Processing

25 September 2014

Health, Pharmaceutical, and Biotechnology Alert

On 19 September 2014 the Office of Inspector General for the U.S. Department of Health and Human Services (OIG) released a report reviewing the effectiveness of safeguards that pharmaceutical manufacturers have in place to ensure that Medicare Part D beneficiaries do not use copay coupons. In conjunction with the report, the OIG also issued a Special Advisory Bulletin (SAB) that reiterates the legal risks presented by copay coupons under the federal Anti-Kickback Statute (AKS) insofar as they induce a beneficiary to purchase a drug reimbursable under a federal healthcare program, like Medicare Part D. This alert discusses OIG’s finding and the implications for coupon programs.

Read More: OIG Report and Special Advisory Bulletin Identify Vulnerabilities in Copay Coupon Processing

The team

Loading data